A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States

被引:19
|
作者
Patel, Bijal Nitin [1 ]
Audet, Patricia R. [1 ]
机构
[1] Univ Sci, Mayes Coll Healthcare Business & Policy, Philadelphia, PA 19104 USA
关键词
MEDICATION THERAPY MANAGEMENT; BENEFIT DESIGN; PHARMACISTS; HEALTH; CARE;
D O I
10.1007/s40273-014-0196-0
中图分类号
F [经济];
学科分类号
02 ;
摘要
With increased innovation and development of specialty pharmaceuticals, the US and global healthcare industries are looking to implement appropriate management strategies to control both utilization and costs. Specialty pharmaceuticals are high-cost medications that treat complex, chronic, rare, and difficult-to-manage conditions. These drugs require special drug handling, appropriate clinical outcomes monitoring, and effective cost controls. The primary scope of this article is to discuss various strategies being implemented for specialty pharmaceutical utilization and cost management and correlated outcomes in the USA; these outcomes include enhanced health insurance plan benefit designs with formulary modifications and greater patient cost burden. Additional methods to manage specialty pharmaceuticals include the use of specialty pharmacies for drug distribution, increased emphasis on coordination of care and evidence-based medicine, as well as healthcare reform and regulations. Healthcare spending, both in the US and globally, continues to increase, with a rising proportion of drug spend towards specialty pharmaceuticals. Continued specialty pharmaceutical innovation and introduction of biosimilar products will evolve the currently utilized management strategies for these drugs.
引用
收藏
页码:1105 / 1114
页数:10
相关论文
共 50 条
  • [1] A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
    Bijal Nitin Patel
    Patricia R. Audet
    [J]. PharmacoEconomics, 2014, 32 : 1105 - 1114
  • [2] MANAGEMENT OF SPECIALTY DRUGS, SPECIALTY PHARMACIES, AND BIOSIMILARS IN THE UNITED STATES
    Brook, R.
    Smeeding, J. E.
    Carlisle, J. A.
    Sax, M. J.
    [J]. VALUE IN HEALTH, 2019, 22 : S304 - S304
  • [3] THE MANAGEMENT OF SPECIALTY DRUGS, SPECIALTY PHARMACIES AND BIOSIMILAR DRUGS IN THE UNITED STATES
    Brook, R. A.
    Smeeding, J. E.
    Carlisle, J. A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A26 - A26
  • [4] Management with specialty pharmaceuticals imminent for various conditions
    Kaufman, Michele B.
    [J]. FORMULARY, 2010, 45 (11) : 359 - 360
  • [5] The Value of Specialty Pharmaceuticals-A Systematic Review
    Zalesak, Martin
    Greenbaum, Joyce S.
    Cohen, Joshua T.
    Kokkotos, Fotios
    Lustig, Adam
    Neumann, Peter J.
    Pritchard, Daryl
    Stewart, Jeffrey
    Dubois, Robert W.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (06): : 461 - 472
  • [6] Anaesthesia in the United States - Anaesthesia is an unpopular specialty in the United States
    Berry, C
    [J]. BRITISH MEDICAL JOURNAL, 1996, 313 (7055): : 495 - 496
  • [7] New approaches to river management in the United States of America
    Hunt, CE
    [J]. NEW APPROACHES TO RIVER MANAGEMENT, 2000, : 119 - 139
  • [8] Financing and Distribution of Pharmaceuticals in the United States
    Dabora, Matan C.
    Turaga, Namrata
    Schulman, KevinA.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (01): : 21 - 22
  • [9] Review of Particulate Matter Management in United States
    Kim, Byeong-Uk
    Kim, Hyun Cheol
    Kim, Soontae
    [J]. JOURNAL OF KOREAN SOCIETY FOR ATMOSPHERIC ENVIRONMENT, 2018, 34 (04) : 588 - 609
  • [10] Marine ecosystem approaches to management: challenges and lessons in the United States
    Barnes, Cassandra
    McFadden, Katherine W.
    [J]. MARINE POLICY, 2008, 32 (03) : 387 - 392